About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

About LymphomaImmune suppression

Last update: 03/13/2014

TOPICS
Introduction | Resources and Research News

Cells of the Immune SystemImmune suppression is a known risk factor for developing lymphomas based on the higher incidence of lymphoma in persons receiving drugs to prevent rejection of transplanted organs from donors.

It's also a known consequence of disease progression. The tumor cells seem to make substances that dampen or distort immune function, or the malignant cells may accumulate in organs involved in immune cell development or maturation, such as the bone marrow, spleen, lymph nodes. 

Immune suppression is also a common side effect of standard treatments, an effect with is generally reversible with time.


See also The Immune System Cancer.gov

Resources:

bullet
[J Nephrol. 1997
Incidence and consequences of post-transplant lymphoproliferative disorders  http://1.usa.gov/O6vumn
bullet
National Cancer Institute
The Immune System and Cancer -  http://1.usa.gov/1fttTgv
bullet
Risk factors for Lymphoma PAL
bullet
Lymphoma Immunization Guide  PAL

Research
News

 

In the News

bullet
{beta}2-microglobulin -[associated with  NHL progression] as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003 Jan 16  PMID: 12531797  PubMed
bullet
Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma. 2002 Jun;43(6):1313-21. PMID: 12153001 PubMed
bullet
The Prevalence of Blastocystis Hominis in Immunosuppressed Patients
 ams.cu.edu.tr

Treatment-related immune suppression

bullet
Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002 Oct;119(1):125-7. PMID: 12358915 PubMed
bullet
Frequency and type of serious infections in Fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002 Apr 1;94(7):2033-9. PMID: 11932906 PubMed
bullet
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002 May;26(5):630-6. PMID: 11979093 PubMed

Infection-
related Immune-dysfunction

bullet
B-cell lymphomas involving the skin associated with hepatitis C virus infection. Int J Dermatol. 2002 Sep;41(9):577-82. PMID: 12358827 - PubMed
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.